The genomic landscape of endocrine-resistant metastatic breast cancer

被引：0
|
作者：
Razavi, P. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-ES4-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ES4-3
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
    Razavi, Pedram
    Chang, Matthew T.
    Xu, Guotai
    Bandlamudi, Chaitanya
    Ross, Dara S.
    Vasan, Neil
    Cai, Yanyan
    Bielski, Craig M.
    Donoghue, Mark T. A.
    Jonsson, Philip
    Penson, Alexander
    Shen, Ronglai
    Pareja, Fresia
    Kundra, Ritika
    Middha, Sumit
    Cheng, Michael L.
    Zehir, Ahmet
    Kandoth, Cyriac
    Patel, Ruchi
    Huberman, Kety
    Smyth, Lillian M.
    Jhaveri, Komal
    Modi, Shanu
    Traina, Tiffany A.
    Dang, Chau
    Zhang, Wen
    Weigelt, Britta
    Li, Bob T.
    Ladanyi, Marc
    Hyman, David M.
    Schultz, Nikolaus
    Robson, Mark E.
    Hudis, Clifford
    Brogi, Edi
    Viale, Agnes
    Norton, Larry
    Dickler, Maura N.
    Berger, Michael F.
    Iacobuzio-Donahue, Christine A.
    Chandarlapaty, Sarat
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Solit, David B.
    Taylor, Barry S.
    Baselga, Jose
    CANCER CELL, 2018, 34 (03) : 427 - +
  • [2] Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor-Positive Breast Cancer
    Sarma, Maithreyi
    Abdou, Yara
    Dhakal, Ajay
    Gandhi, Shipra
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2020, 14
  • [3] mTOR inhibitors: changing landscape of endocrine-resistant breast cancer
    Chumsri, Saranya
    Sabnis, Gauri
    Tkaczuk, Katherine
    Brodie, Angela
    FUTURE ONCOLOGY, 2014, 10 (03) : 443 - 456
  • [4] Endocrine-Resistant Breast Cancer: Mechanisms and Treatment
    Hartkopf, Andreas D.
    Grischke, Eva-Maria
    Brucker, Sara Y.
    BREAST CARE, 2020, 15 (04) : 347 - 354
  • [5] A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer
    Trinh, X. B.
    Sas, L.
    Van Laere, S. J.
    Prove, A.
    Deleu, I.
    Rasschaert, M. A.
    Van de Velde, H.
    Vinken, P.
    Vermeulen, P. B.
    van Dam, P. A.
    Wojtasik, A.
    De Mesmaeker, P.
    Tjalma, W. A.
    Dirix, L. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer
    Trinh, X. B.
    Sas, L.
    Van Laere, S. J.
    Prove, A.
    Deleu, I.
    Rasschaert, M.
    Van De Velde, H.
    Vinken, P.
    Vermeulen, P. B.
    Van Dam, P. A.
    Wojtasik, A.
    De Mesmaeker, P.
    Tjalma, W. A.
    Dirix, L. Y.
    ONCOLOGY REPORTS, 2012, 27 (03) : 657 - 663
  • [7] The NFκB pathway and endocrine-resistant breast cancer
    Zhou, Y
    Eppenberger-Castori, S
    Eppenberger, U
    Benz, CC
    ENDOCRINE-RELATED CANCER, 2005, 12 : S37 - S46
  • [8] Gene expression profiles in endocrine-resistant breast cancer
    Schagerholm, C.
    Robertson, S.
    Sifakis, E. G.
    Hases, L.
    Williams, C.
    Hartman, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S640 - S640
  • [9] Breast cancer: Recurrent fusions in endocrine-resistant disease
    Romero D.
    Nature Reviews Clinical Oncology, 2018, 15 (4) : 200 - 200
  • [10] Epigenetic Therapy Targets Endocrine-Resistant Breast Cancer
    Genetic Engineering and Biotechnology News, 2024, 44 (04): : 34
12345